Barely a week into his second term, Trump has issued several executive actions that are reshaping DEI programs across the federal government and corporate America. Since his inauguration on January 20,

Federal agency workers say that professional groups meant to support employees, many of whom are from marginalized backgrounds, are under threat from President Donald Trump’s DEI executive order.

The Food & Drug Administration (FDA), has quietly taken down their guidance detailing diversity action plans for clinical trials. Could this cut to DEI cost lives?